拉巴胺对系统性红血性狼中的内皮功能有好处
Hyoseon Kim1, Michael P Massett1
1Department of Kinesiology and Sport Management, Texas Tech University, Lubbock, TX, United States.
Frontiers in physiology
|September 5, 2024
概括
用拉巴胺素抑制哺乳动物目标拉巴胺素复合物1 (mTORC1) 改善了狼小鼠内皮功能. 这表明mTORC1抑制可能是系统性红斑狼 (SLE) 的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
背景情况:
- 内皮功能障碍是系统性红斑狼 (SLE) 的一个标志.
- 在SLE中观察到拉帕素复合体1 (mTORC1) 信号的哺乳动物标升高.
- mTORC1在SLE相关的内皮功能障碍和线粒细胞衰变中的作用尚不清楚.
研究的目的:
- 调查用拉巴胺抑制mTORC1是否可以改善SLE中的内皮功能.
- 为了确定拉帕米辛治疗是否会影响SLE模型中的线粒细胞衰变和炎症反应.
主要方法:
- 易患狼 (MRL/lpr) 和对照 (MRL/MpJ) 的雌性小鼠接受了拉帕米或对照治疗.
- 评估了依赖内皮细胞 (乙胆) 和独立的 (酸) 血管松.
- 分析了mTORC1活动,线粒细胞衰变标志物和炎症标志物 (VCAM-1).
主要成果:
- 拉帕米辛显著抑制了狼小鼠的mTORC1活性升高.
- 狼小鼠的内皮功能障碍是通过拉帕米辛治疗来预防的.
- 拉巴胺在狼小鼠中降低了炎症标记物和调节了线粒细胞衰变标记物.
结论:
- 用拉巴胺素抑制mTORC1对SLE的内皮功能产生有益影响.
- 炎症和改变的线粒细胞衰变与SLE诱导的内皮功能障碍有关.
- mTORC1抑制代表了管理与SLE相关的血管并发症的潜在治疗途径.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
142
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142


